Similar to lung and breast cancer, TLR7 agonists (eg., imiquimod) activate the immune response in skin cancers (melanoma, squamous cell carcinoma, and basal cell carcinoma) and several agonists are currently in clinical trials for melanoma (imiquimod (NCT01678352) and resiquimod (NCT01748747)) [57, 58, 61]. Here, TLR7 is linked to breast carcinoma.